Concord Gets the Green Light—USFDA Gives Dholka Site a Clean Bill of Health

Concord Biotech Ltd (NSE: CONB.NS) has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) facility at Dholka, Gujarat, officially closing the recent inspection with a "No Action Indicated" (NAI) status. The outcome confirms that the facility meets all the applicable regulatory norms and does not require any further remediation measures.

 

1. Inspection Timeline and Outcome

2. Strategic Significance

3. Company Snapshot

Sources: Economic Times, Concord Biotech